Abstract Immunohistochemical studies showed that O 6 -methylguanine-DNA methyltransferase (MGMT) protein expression is negatively associated with survival in glioblastomas treated with alkylating agents in accordance with previous results of methylation-speciWc PCR. Implementation of this data in routine clinical diagnostics is limited due to often inappropriate study designs, e.g. pooling of tumor entities, WHO grades or primary and secondary glioblastomas, disregard concerning the inWltration zone or various epidemiological factors. The aim of our study was to evaluate MGMT expression and its prognostic value taking into consideration the aforementioned deWciencies. For this, 162 astrocytic tumors WHO II-IV (36 diVuse astrocytomas WHO II, 51 anaplastic astrocytomas, 75 primary glioblastomas) as well as 25 glioblastoma inWltration zones and 19 glioblastoma relapses were analyzed for immunohistochemical MGMT protein expression using tissue microarray technique. Expression of MGMT signiWcantly decreased from WHO grade II (25.6%) to glioblastoma (16.8%, p = 0.01) with lowest levels in grade III tumors (10.2%, II/III p < 0.0001). SigniWcant negative associations of MGMT and survival were detected for WHO grade II and IV (p = 0.003 and 0.013). The optimal cut-oV value of MGMT positive nuclei in primary glioblastomas discriminating patients with signiWcantly diVerent survival rates was at 15% (Log-Rank p = 0.0002). Individual relapse tumors showed changes of MGMT expression to a varying degree. The inWltration zone demonstrated a signiWcant increase of MGMT (p < 0.0001). We conclude that immunohistochemical MGMT assessment has potential as a powerful diagnostic tool but analysis should only be performed in a grade dependent manner, before radio-/chemotherapy and with special attention to the inWltration zone of diVuse astrocytomas.
Introduction
Recently, the EORTC (European organisation for research and treatment of cancer) study with temozolomide in conjunction with radiotherapy after surgical resection demonstrated a signiWcantly prolonged median patient survival, albeit only for single months [40] . Further analysis of the DNA-repair gene MGMT (O 6 -methylguanine-DNA methyltransferase also known as AGT, NC-IUBMB: E.C.2.1.1.63) methylation status demonstrated a signiWcant survival beneWt solely for patients with a silenced MGMT gene as detected by methylation-speciWc polymerase-chainreaction analysis (MSP) in the group treated with radio-/ chemotherapy [16] . This conWrmed previous results of a correlation of MGMT inactivation and clinical response to alkylating agents (e.g. temozolomide, nitrosourea) [11, 12, 18] .
Besides MSP [11, 15, 34, 46] and RNA detecting methods [33, 42] , the measurement of MGMT enzyme activity and the immunohistochemical (IHC) detection of MGMT protein have been employed repeatedly to assess the in vivo MGMT status [1, 8, 25, 39, 48] . In a recent comparison a signiWcant correlation of IHC MGMT evaluation with MSP as well as MGMT enzyme activity was demonstrated, while discordance concerning the prognostic properties of MSP and IHC MGMT detection was assumed [23] . The explanatory power of this analysis remains limited though, as only a small number of pooled tumor samples were investigated and the prognostic groups were not conWrmed with an actual survival beneWt. If MGMT status is intended to guide future therapeutic practice the need for further standardization of MGMT testing is urgent.
Immunohistochemistry (IHC) presents several advantages for the detection of MGMT status, predominantly technical aspects (fast and easy to do, little material required, endothelia as internal positive control, material can be archived in paraYn, antibodies commercially available with mostly used clone mT3.1, see [5] ) but also oVers additional diagnostic information such as the visual discrimination of tumor cells from non-neoplastic cells. There is strong evidence for clonal heterogeneity of gliomas for MGMT methylation [2] and that modiWcations besides promoter methylation such as MGMT mutations or p53 derangement may aVect the functional in vivo protein levels [3, 9] . By measuring the endpoint of these regulations, IHC MGMT detection avoids several of these pitfalls. Nevertheless, IHC has several shortcomings, in particular tumor inWltration by MGMT positive inXammatory cells [29] , as well as the possible induction of MGMT by radio-/chemotherapy [13, 47] . The main problem with the interpretation of IHC MGMT status though, is an often insuYcient study design. Glial tumors of various WHO grades with known prognostic diVerences or primary and secondary glioblastomas are pooled in a single group and analyzed for prognosis, the total sample size is often low, and cut-oV values have been selected arbitrarily.
In the current study we have addressed several of the above shortcomings of IHC MGMT detection and attempted to establish non-arbitrary cut-oV values for future prospective studies as well as routine clinical evaluation.
For this purpose, the IHC expression of MGMT is analyzed in a large array of diVuse astrocytomas of WHO grades II, III and IV, and associations with survival are evaluated independently for each grade. For grade IV, only primary glioblastomas at Wrst occurrence are taken into analysis. To evaluate if radio-/chemotherapy has an impact on in vivo MGMT expression of glioblastomas, primary glioblastomas are investigated before and after therapy. Finally, special attention is given to inWltration versus central areas of glioblastomas. [20] . For grade IV, only primary glioblastomas were analyzed. Resection data as determined postoperatively by the neurosurgeon was available for 147 cases with 50 cases of complete macroscopic resection and 97 cases with incomplete resection. No tumor biopsies were integrated into this study. Additionally, 25 inWltration zones and 19 relapses of glioblastomas were included. All patients with relapse received Weld radiotherapy of up to 60 Gray and chemotherapy to a varying degree. Of six tumor specimens normal appearing white matter distant from the tumor was analyzed as a reference of MGMT expression in uninWltrated brain. Usage of the tissue was approved by the local ethics committee.
Materials and methods

Human tissue specimens
Follow up for glioma patients was up to 12.6 years. Within this time frame a total of 99 patients died after a median survival of 13.9 months (range 1-151) whereas 54 were still alive with a median follow-up of 27.6 months (range 1-136). Nine patients were lost the trace immediately after operation. These patients were not included in survival analysis.
All specimens were Wxed in 4% formalin (pH 7.4), embedded in paraYn and representative tissue samples were prepared as a tissue microarray (TMA) (punch diameter, 0.6 mm) as previously described [27] . The TMA blocks were cut with a microtome (3 m thickness) and placed on SuperFrost Plus slides (Microm International, Walldorf, Germany).
Immunohistochemistry
The slides were deparaVinized in chloroform for 20 min then rehydrated in descending series of ethanol and washed in Tris-buVered saline (TBS). For antigen retrieval we used a simpliWed adaptation of the method introduced by Namimatsu and colleagues [30] , boiling the slides in 0.05% citraconic anhydride (pH 7.4) in a microwave oven at maximum power (800 W) for 20 min, and then let the slides cool down to room temperature. Endogenous peroxidase was blocked with 3% H 2 O 2 in methanol for 15 min, and standard swine serum was applied for 15 min to prevent nonspeciWc binding. As primary antibody we used monoclonal mouse anti-MGMT antibody clone MT3.1 (Chemicon, Temecula, USA) in a dilution of 1:75 and sections were incubated overnight at 4°C. Subsequent to washes in TBS for 10 min, sections were incubated for 30 min with the secondary antibody at room temperature. The peroxidase-conjugated avidin-biotin complex (ABC) technique (Dako, Hamburg, Germany) with diaminobenzidine (DAB; Sigma, Deisenhofen, Germany) as chromogen was used to visualize the antigen binding. All sections were counterstained with hemalaun.
As negative controls (isotype control), every slide was also treated with replacement of primary antibody with a monoclonal IgG 1 antibody for an Aspergillus niger surface protein (Dako Cytomation), a protein structure not expressed in mammalian tissue. None of the tumors showed an unspeciWc nuclear stain.
Evaluation
Evaluation of the immunohistochemical staining and photographic documentation was performed using an Olympus Vanox AHBT3 microscope. All slides were investigated individually by two experienced investigators and a mean score of both observations was used for statistics. Four cases were not possible to evaluate and were omitted from further analysis (see "Results"). At least 100 cells were evaluated for nuclear MGMT staining. Endothelial cells and perivascular lymphocytes were omitted from analysis. A weak staining of the nucleus was counted as positive. Granular staining of the nucleus was not observed. Cytoplasmic staining was not counted as positive.
Statistical analysis
The means were compared by a one-way analysis of variance (ANOVA) with subsequent Tukey-Kramer's HSD test with a global signiWcance level of 5%. For signiWcant diVerences individual p values were calculated. For individual pairwise comparisons we used a one sample t test. For assessing correlations between age and MGMT expression an analysis of linear regression was used. The means are given together with their 95% conWdence intervals (CI), signiWcant diVerences are illustrated (*p · 0.05, **p · 0.01, ***p · 0.0001). We chose a two-step survival analysis with the validation of a global association in an exponential parametric survival Wt for each grade and a subsequent Kaplan Meier analysis. A signiWcant global association with survival was set as a requirement to perform the dichotomy of the percental values for Kaplan Meier analysis. Grades II and IV met the above requirements and were repeatedly divided into two groups at 5% intervals for optimal cut-oV values. A designated group was never allowed to be less than Wve patients. For adjustment of the p values due to multiple testing we used the method of Bonferroni. JMP IN (http://www.JMP.com) was used for statistical analysis.
Results
MGMT expression decreases signiWcantly from low to high-grade gliomas
The vast majority of cases investigated demonstrated a moderate to strong nuclear stain for MGMT in at least some tumor cells (Fig. 1a-c) . Generally, most endothelial nuclei as well as inWltrating inXammatory cells were strongly MGMT positive and endothelial nuclei served as an internal positive control. In endothelia, an additional weak cytoplasmic stain was regularly observed (Fig. 1a) . As previously noted, we observed a droplet like cytoplasmic stain in few cases (one case of grade II, 11 cases of grade III) [24] . Matching these cases with the isotype control revealed that the staining does not represent cytoplasmic MGMT, but is nonspeciWc (Fig. 1d, e) . Importantly, no cases with an unspeciWc nuclear reaction were observed in the isotype control. Four cases (one grade II, one grade III, two grade IV) could not be evaluated for MGMT expression by IHC, as the nuclear reaction was too weak to clearly diVerentiate positive and negative cells (Fig. 1f) . The average levels of stained tumor cells were higher in low grade compared to high grade tumors with a mean expression of 25.6% (CI 20.1-31.1%) in diVuse astrocytoma WHO grade II, decreasing to 10.2% (CI 5.6-14.8%) in anaplastic astrocytoma grade III and 16.8% (CI 13.0-20.6%) in glioblastoma WHO grade IV (Fig. 2) . The decrease was signiWcant (II/III p < 0.0001; II/IV p = 0.01) while the signiWcance between grade III and IV was lost after correction for multiple testing (III/IV p = 0.031). Six tumor cases with uninWltrated white matter showed high levels of positive glial cells [mean 77.2% (CI 60.7-93.6%)] and all demonstrated a clear reduction of MGMT-positive nuclei in the tumor tissue (data not shown). Expression in uninWltrated grey matter was lower than in white matter with neurons generally negative for MGMT (data not shown).
MGMT expression is signiWcantly higher in glioblastoma inWltration zone compared to tumor center A highly signiWcant increase of nuclear MGMT expression was observed in the inWltration zone of the investigated glioblastomas compared to the corresponding tumor center (p < 0.0001). The mean expression was 43.9% (CI 35.3-52.5%) in the inWltration zone compared to 16.1% (CI 7.7-24.5%) in the subset of glioblastomas (Fig. 3) . The mean expression of the inWltration zone was clearly lower than the mean expression of uninWltrated white matter (see above).
In vivo MGMT expression does not shift unidirectionally after radio-/chemotherapy While the mean expression of MGMT in the group of relapse glioblastomas demonstrated an increase from 14.3% (CI 6.9-21.6%) in the primary tumors to 20.4% (CI 13.1-27.7%) in the relapses, a matched pairs analysis could not show signiWcant diVerences (p = 0.20; Fig. 4) . Several tumors demonstrated a considerable change of individual MGMT expression, but both, a clear increase as well as a clear decrease was observed. Three change of expression groups were distinguished in relation to the mean diVerence of all cases, one group with a clear decrease of MGMT (red, n = 5 of 19) with a reduction beyond the CI of the mean diVerence, the second with no individual changes (black, n = 7 of 19) (diVerence within 95% CI) and the third with a clear increase of MGMT out of the range of the 95% CI (yellow, n = 7 of 19). No further association of the groups with individual chemotherapy was seen (data not shown).
MGMT is negatively associated with survival in WHO grade II and IV The survival analysis for WHO grade II, III and IV tumors showed a signiWcant association in the parametric exponential survival Wt of grades II and IV (p = 0.003 and 0.013, respectively; Figs. 5, 6) while grade III tumors demonstrated no such association (p = 0.18, data not shown). Even for the subgroup of WHO grade III tumors that received an alkylating therapy (n = 19) no signiWcant results were obtained (p = 0.88, data not shown). For both grades II and IV, low levels of MGMT were associated with a better patient survival. Further analysis for an optimal cut-oV value for prognostic evaluation demonstrated that for grade II, MGMT expression in 35% of the tumor cells was the delimiter with the best p value ( Table 1) . The median survival was 44.4 months (mean 63.8, range 1-151) for low MGMT expression in contrast to 10.4 months (mean 31.6, range 3-89) in the high MGMT group. The division of WHO grade II cases at 35% led to two groups of clearly diVerent size, indicating that a small group of patients with high MGMT expression (n = 6) were predominantly responsible for the association with survival.
In grade IV the optimal value for a dichotomy was found at 15% MGMT positive cells (Table 1 ). This value highly discriminated between patients with a good prognosis and patients with a poor prognosis (Log-Rank p = 0.0002; Fig. 6 ). Median survival for the group with low expression 
Correlation of MGMT expression and patient age
In the analysis of associations between MGMT expression and patient age a marginally signiWcant positive correlation was detected for grade II and a strong trend for grade IV (p = 0.046 and 0.052; Fig. 7) , whereas WHO grade III displayed no association (p = 0.27; data not shown).
As for grade II all patients with a worse prognosis were old (Fig. 7a) , it seems evident that for grade II the association of MGMT expression and survival was predominantly by the diVerence of age, which is a well-known predictive factor of survival.
MGMT retains its association with survival in peak age group of glioblastoma To verify that the association of MGMT with survival in glioblastoma is not an eVect of its near correlation with age ( Fig. 7b) , glioblastoma cases were reduced to the peak age group of patients from 45 to 70 years [20] , thus omitting patients with extreme age deviations from the analysis. Even for the smaller sample group the signiWcance for the association with survival remained in the exponential parametric survival Wt (p = 0.035; Fig. 8a ) as well as in the Kaplan Meier analysis with a signiWcant discrimination of patients with good and bad prognosis at the previously established cut-oV value of 15% (p = 0.011; Fig. 8b ). For the reduced group, no association of patient age and MGMT expression was detectable (p = 0.147, data not shown).
Discussion
Future glioma therapy will consider tumor MGMT status and possibly stratify patients by their MGMT expression [14] . Several studies using methods such as MSP and IHC have demonstrated an association of MGMT status and survival (IHC [1, 7, 12, 29, 35] ; MSP [10, 11, 15, 16, 34, 45] ) while other groups could not or only partially detect associations with survival [2, 4, 19] . Recently in reaction to an IHC study of MGMT in inoperable newly diagnosed glioblastoma patients [7] , MSP was clearly advocated for the detection of MGMT status [41] .
It is worth mentioning that MSP also has distinct shortcomings. Astrocytomas are very heterogeneous tumors, both in histology and (epi)-genetics, and this is also true for the methylation of the MGMT promoter as demonstrated by Blanc et al. [2] . In a recent comparison of IHC and MSP, Maxwell noted that even in MSP negative tumors (where MGMT is not silenced) a large fraction of potentially temozolomide sensitive MGMT negative cells is present and in MSP positive tumors (where MGMT is silenced) large fractions of MGMT positive cells can be found. MSP has the great advantage of oVering an explicit MGMT status, though it seems as if the method artiWcially divides gliomas into black and white, and does not take into account the heterogeneous nature of these tumors. This makes therapeutic decisions on the basis of MSP status alone somewhat unsatisfactory. It is possible, that MGMT methylation status functions as a surrogate for multiple gene silencing activities throughout the tumor with the inactivation of further prognostically relevant genes. This theory may also explain why several investigators have observed an MGMT survival beneWt irrespective of actual treatment with an alkylating agent [10, 16] . Other results are further detaching MGMT methylation status from actual cellular MGMT levels, as recently p53 has been shown to regulate cellular MGMT independently of methylation status [3] . A possible reason why IHC has not (yet) found its way into clinical routine may be the lack of consistently deWned cut-oV values for prognostic groups. Some of the discrepancies could be explained by the investigation of diVerent patient collectives. Indeed, as our results indicate a trend of increased MGMT expression in old age, variations in the mean age of investigated patients may well change the optimal cut-oV value. We therefore established the cut-oV for the peak age group of glioblastoma as deWned in the WHO ClassiWcation [20] . Further, our results were able to demonstrate a signiWcant decrease from low to high-grade diVuse astrocytoma, an observation that is supported by other studies [26, 36, 48] and clear diVerences between grade III and IV tumors. This clearly disqualiWes the pooling of astrocytoma grades for survival analysis. Our study did not integrate secondary glioblastomas for the reasons that (1) the genetic pathways leading to primary or secondary glioblastoma diVer at several levels [32] , (2) secondary glioblastomas only constitute a small subgroup of glioblastomas [31] , (3) p53 levels, known to inXuence MGMT status, clearly diVer in primary and secondary glioblastoma [44] , and (4) the methylation of MGMT promoter shows signiWcantly higher levels in secondary glioblastomas [28] .
All these factors may in part explain the wide range of cut-oVs in use for "high-grade" glioma ranging from <5 to 35% [1, 4, 7, 12, 29, 35] . As Table 2 indicates, most IHC studies conducted so far pooled several WHO grades, some even oligodendroglial and astrocytic tumors. Of the two studies with values exclusive for grade IV, Chinot et al. [7] investigated the subgroup of inoperable tumors, a group b Kaplan Meier analysis at the previously established cut-oV value of 15% also remains signiWcant for the peak age group with a survival not comparable to the general patient collective and in the study of Anda et al. [1] analysis was limited to 18 primary glioblastomas. Further factors that are likely to inXuence the results are technical factors of the IHC procedure and interobserver variability. For a standardized IHC procedure we performed an adoption of the antigen retrieval method of Namimatsu et al. [30] . Interobserver variability should be evaluated in a larger multi-institutional study to determine the number of patients ending up in divergent prognostic groups, thereby further elucidating the feasibility of IHC MGMT status detection with our proposed cut-oV.
In this study on astrocytic tumors, only grade II and IV tumors demonstrated an association with survival, whereas grade III tumors did not. Likewise, Brell demonstrated a lack of association of MGMT methylation with survival as well as MGMT IHC for a pooled group of grade III gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) [4] . It is noteworthy that Brell and colleagues demonstrated an association of IHC and survival in a secondary analysis of a subgroup of patients treated with an alkylating agent, whereas the same analysis remained insigniWcant in our cohort. Thus, it is possible that the results of Brell were strongly inXuenced by the inclusion of tumors with an oligodendroglial diVerentiation which are potentially more susceptible to chemotherapy [6] , whereas for anaplastic astrocytomas even post-alkylating therapy survival seems to be independent of MGMT status. Our results give new input to the current discussion on the lack of justiWcation for temozolomide as the Wrst line treatment for anaplastic astrocytoma (reviewed in [38] ). In contrast, MGMT expression was elevated in WHO grade II tumors and uninWltrated white matter, indicating that their DNA repair mechanisms function on a higher level. In general, this seems desirable, as high MGMT levels are likely to counteract genetic alteration (e.g. spontaneous mutations by endogenous DNA alkylation) that might lead to tumor development and progression [22] . For the treatment of low-grade astrocytomas this poses a problem though, as several therapeutic substances depend on a reduced DNA repair mechanism of tumor cells.
A recent MGMT methylation study of 27 Wbrillary astrocytomas grade II could not detect a signiWcant relationship with overall survival [46] while a cohort of 49 grade II astrocytomas identiWed MGMT methylation even as an adverse indicator of recurrence free survival [21] . Data concerning the time to relapse could not be integrated into this study because of the small number of assessable cases. Two explanations for the discrepancy to our results are conceivable. (1) Our group of grade II tumors did not entirely consist of Wbrillary astrocytomas given that Wve gemistocytic and two protoplasmic tumors were also included. For gemistocytic astrocytomas a more aggressive behavior has been described [20] . In an analysis omitting these tumors, the parametric survival Wt remained signiWcant (p = 0.016), proving that these tumors are not causing the discrepancy. (2) Our data for grade II demonstrated a signiWcant positive correlation to patient age with expression above 35% exclusively found in patients above 50 years. To our knowledge, a signiWcant positive association of age and MGMT expression in WHO grade II tumors has not been described to date. This association may partially contribute to the very strong prognostic power of age in grade II tumors [31] ; on the other hand it complicates the interpretation of the presented data. Our cut-oV of 35% for grade II, forming one small group of old patients with high expression and bad prognosis does not suit the standards that we aimed to establish by this study and therefore we suggest further evaluation on the signiWcance of MGMT in diVuse astrocytoma WHO grade II.
Our study represents the largest observation of IHC MGMT expression in primary glioblastoma before treatment and oVers a highly signiWcant cut-oV value for the further evaluation of prognostic groups. To our knowledge a [37] . The discrepancy of high protein levels and low enzyme activity could possibly be explained by several loss of function mutations in the MGMT gene that have been identiWed in mutagenesis studies, although the in vivo prevalence of these mutations has not been documented [9] . However, the results of other studies could demonstrate a signiWcant correlation of MGMT enzyme activity and immunohistochemical labeling [23] , casting the above explanations into doubt and oVering a sampling eVect as a more likely reason for the discrepancy. A further aspect we tried to elucidate with this study was the proposed induction of MGMT by radio-/chemotherapy [13, 47] . For this, a cohort of primary glioblastomas was analyzed before and after radiotherapy and alkylating chemotherapy. No statistically signiWcant unidirectional change of MGMT expression was detected although almost three-quarter of the tumors showed marked changes out of the CI range of their MGMT proWle. The cause of these changes remains enigmatic. In contrast, Nakasu et al. [29] could not detect changes of MGMT expression in recurrent gliomas in a smaller cohort. Still, our results lead us to the conclusion that considerable changes can be observed after therapy and our proposed cut-oV value of 15% should only be applied before application of radio-/chemotherapy. In case of a relapse the reevaluation of MGMT tumor status seems necessary.
Besides chemotherapy other drugs have also been implicated in interfering with MGMT expression with contrary results found in literature, foremost glucocorticoids [17, 43] . Although many of our high-grade astrocytoma patients received dexamethasone, the dosages and application intervals before operation were not traceable and no statistical analysis regarding this question could be performed.
In an analysis of further possible sources of error the inWltration zone of diVuse astrocytoma demonstrated a considerable increase of MGMT. It is important to note that a clear histological discrimination of tumor cells and inWltrated normal brain cells was not possible. As we observed high levels of MGMT in normal brain astrocytes and oligodendrocytes, the high levels in the inWltration zone most probably represents residual non-neoplastic cells [29] . This Wnding is problematic for several methods of MGMT detection. In IHC, small samples of tissue might only contain inWltration zone and might therefore be perceived as falsely high MGMT expressing tumors; MSP analysis might reveal false negative results as the proportion of tumor cells in the selected material might be too low. Highgrade gliomas are further known to be inWltrated by MGMT positive non-neoplastic cells (mostly lymphocytes and macrophages/microglia) constituting up to 7% of the total tumor cells [29] . In IHC, it is often not possible to distinguish monocytes from neoplastic astrocytes in routine staining and routine immunohistochemical double staining is not practicable. As our proposed cut-oV of 15% lies well beyond the observed maximum of 7% non-neoplastic cells, we conclude that these cells are generally summed up in the group of low expression and in general will not further interfere with the evaluation.
As we aspire to propose a standardized procedure for immunohistochemical evaluation several points for routine diagnostics need to be addressed: What region of the tumor should be evaluated? In this study we selected areas with the most prominent signs of atypia/anaplasia, especially cellular density and nuclear polymorphism. Still cases with diverging MGMT expression in equally atypical regions may be observed; in this case we propose evaluating the area with the higher staining indices as these cells supposedly determine survival. When is an MGMT stained cell counted as positive? Equivalent to the staining of p53 and other nuclear markers like progesterone receptor the MGMT staining is not of an on/oV type, as every shade of staining was detected. This is a risk for a signiWcant observer bias. In our investigation we decided to even count weak staining as positive, as results with the highly sensitive nested in situ RT-PCR indicated that immunohistochemical evaluation underrate the actual MGMT protein expression [33] . What about the inWltration zone? We propose that immunohistochemical evaluation should only be performed when the tumor can be unequivocally identiWed. Especially in low-grade diVuse astrocytoma this can cause serious problems. In cases of uncertainty we propose not to evaluate MGMT by IHC alone. What cells should be evaluated? We propose to count all cells except vascular endothelia and perivascular lymphocytes as our cut-oV is suYciently high to ensure that counted macrophages/ microglia will not alter prognostic status. A further discrimination is simply not workable for fast routine diagnostics.
In conclusion, we were able to demonstrate that the evaluation of MGMT status for glioma should be performed strictly grade dependent. We propose further investigations of the relation of survival and MGMT expression in grade II and urge to analyze the eVect of age adequately in further studies. The lack of association with survival in grade III may be a representation of the diVerent biological behavior and altered response to chemotherapy although further studies are needed to verify our results. As even the patients receiving alkylating therapeutics showed no association of survival and MGMT, possibly other Wrst-line therapeutic approaches should be sought for WHO grade III astrocytomas.
For de-novo grade IV glioblastomas we were able to establish an optimal cut-oV value of 15% MGMT positive nuclei for maximal discrimination of prognostic groups.
Finally, we conclude that the current methods of identifying MGMT status should not lead to a status dependent therapy with possibly not treating MGMT positive patients, as the heterogeneous aspect of every investigated tumor indicates a fraction of potentially chemotherapy sensitive cells. If patient tailored therapy is sought, further understanding of MGMT regulation and further molecular determinants of survival are urgently needed.
